Compare GE Vernova Inc (GEV) vs HCA Health Inc (HCA) Price & Performance

GE Vernova (GEV) trades at $1,038, down 2.63% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong profitability with 23.81% net income margin and 83.23% ROE, though valuation metrics appear elevated with P/E of 30.84 and EV/EBITDA of 109.82. Recent earnings showed volatility with Q1 2026 beating expectations by a wide margin, while the company prepares for Q2 2026 results amid significant AI-driven power demand growth.

The outlook remains positive with analyst consensus strongly bullish (21 buy ratings, 0 sell) and $1,260 price target representing 21% upside. Key opportunities include AI data center power demand and $11 billion investment push, while risks include wind segment pressures and elevated valuation multiples that may limit near-term upside potential despite strong fundamentals.

HCA Healthcare (HCA) trades at $389.90, up 7.23% over the past 24 hours, with strong recent earnings beats but a bearish technical signal. The stock shows solid fundamentals with 2025 revenue of $75.60B and net income of $6.78B, supported by a P/E of 13.05 and net margin of 8.89%. However, recent news highlights guidance cuts due to payer mix shifts and rising uninsured patients, creating near-term headwinds.

The outlook is mixed: analyst consensus remains bullish with a $469.40 price target, but technical indicators and recent guidance reductions suggest caution. Key risks include margin compression and debt levels, while long-term growth drivers like capacity expansion and gene therapy research offer potential upside. Investors should weigh strong valuation metrics against operational challenges.